James Fadiman and Jordan Gruber: Psychedelics Legalization Will Continue No Matter Who Is President
Mar 26, 2025
auto_awesome
James Fadiman, a Stanford-trained psychologist and pioneer in microdosing, teams up with Jordan Gruber, co-author on health benefits of psychedelics. They dive into how microdosing can alleviate depression and enhance cognitive function, likening it to a vitamin regimen. The duo tackles the shifting landscape of psychedelic legalization, discussing its cultural normalization regardless of political climate. They also reflect on the growing acceptance of psychedelics in therapy, emphasizing the potential for societal transformation and healing.
Microdosing involves small, sub-perceptual doses of psychedelics like LSD or psilocybin, offering potential benefits for mental health and focus.
The current cultural renaissance surrounding psychedelics is driven by positive user experiences and an increasing normalization of their therapeutic use.
Despite political shifts, the momentum for psychedelics legalization is likely to continue, fueled by evolving research and grassroots advocacy.
Deep dives
Understanding Microdosing
Microdosing involves taking subperceptual doses of classic psychedelics, such as LSD or psilocybin, to improve mental health and performance. Instead of acting like a small high dose, microdosing is treated more like a vitamin, allowing the body to improve over time without the intense experiences associated with higher doses. Popular protocols typically suggest dosing every few days with breaks in between to maximize benefits. The approach has grown in interest due to anecdotal experiences and emerging research that hint at potential positive effects on mood, focus, and overall well-being.
The Cultural Shift Toward Psychedelics
The past two decades have seen a cultural renaissance around psychedelics, driven by a growing openness to their benefits and the increasing normalization of their use. A rise in reports from users, particularly in Silicon Valley, has played a pivotal role in this resurgence, as individuals share their positive experiences with microdosing. Authors Jim Fadiman and Jordan Gruber highlight the importance of recognizing this shift as interest escalates, leading to more discussions and scientific inquiries into the potential therapeutic uses of psychedelics. The public’s fascination has also prompted publishers to act quickly to release books and resources on the subject, indicating a significant change in societal attitudes.
Addressing Depression and Other Issues
Microdosing is increasingly used as an alternative for individuals suffering from treatment-resistant depression and other mental health challenges. Many users report a return to their pre-depression self, stating that microdosing alleviates symptoms that conventional medications had failed to address. The trend indicates that individuals often experience improved focus and mood, suggesting a broader spectrum of positive mental health outcomes. Encouragingly, therapists observe that patients who microdose tend to engage more effectively in therapy sessions, fostering a sense of hope for those who have struggled with traditional treatment options.
Microdosing Versus Other Psychedelics
While substances like MDMA and ketamine are gaining traction in therapeutic contexts, they diverge from the principles of microdosing, primarily due to their different psychoactive effects. MDMA functions more like an amphetamine at lower doses, while ketamine is classified as a dissociative, which may not align with the protocols for microdosing. Fadiman and Gruber emphasize that classic psychedelics specifically have unique properties that support neuroplasticity and emotional equilibrium, which microdosing taps into. The distinction reinforces the idea that microdosing is not merely a diluted form of high-dose psychedelics but operates in its own therapeutic realm.
The Future of Legalization and Research
The future of psychedelics in mainstream medicine hinges on continued research and cultural acceptance, with indications that shifts in legality are likely to evolve regardless of political changes. As more young professionals enter the medical field with an interest in psychedelics, the dialogue surrounding their acceptance and potential therapeutic benefits is expected to grow. Emerging studies and anecdotal evidence are paving the way for increased legitimacy, especially among veterans seeking alternatives for PTSD treatment. This landscape reveals a powerful interaction between grassroots movements and bureaucratic progress, underscoring the potential for legal and societal changes in approaching psychedelics.
You've probably heard about microdosing, which involves taking a small, "sub-perceptual" dose of psychedelics like LSD or psilocybin on a regular basis to ward off depression, anxiety, and chronic pain—or to optimize focus and boost energy.
Today's guests are James Fadiman and Jordan Gruber, authors of the new book Microdosing for Health, Healing, and Enhanced Performance. Fadiman, a Stanford-trained research psychologist who has been working with psychedelics since the early 1960s, popularized the concept of microdosing over a decade ago. They talk with Reason's Nick Gillespie about the mechanics of and theory behind microdosing, its promise and limits, and how it fits into the larger psychedelic renaissance that has been flowering for most of the 21st century. And they discuss the prospects for legalization and cultural normalization of psychedelics under the Trump administration.
1:19 — New book: Microdosing for Health, Healing, and Enhanced Performance 5:12 — How Fadiman discovered microdosing 8:10 — How Gruber began microdosing 8:57 — Microdosing is similar to a vitamin protocol 11:17 — MDMA, ketamine, and cannabis work differently 12:50 — Microdosing for depression 16:02 — Other conditions microdosing could help alleviate 19:09 — Is microdosing for life? 21:17 — How to quantify the efficacy of microdosing 30:14 — Psychedelics and drug law 37:30 — Psychedelic-assisted therapy 39:40 — Psychedelics and their benefits are nonideological 46:15 — Fadiman and Gruber's 2020 book: Your Symphony of Selves 53:45 — Drug legalization under Donald Trump
Today's sponsor:
The Reason Speakeasy. The Reason Speakeasy is a monthly, unscripted conversation in New York City with outspoken defenders of free thinking and heterodoxy in an age of intellectual conformity and groupthink. It doubles as a live taping of The Reason Interview With Nick Gillespie podcast. The next one takes place on Tuesday, April 8, with Jeffrey Singer, who recently authored Your Body, Your Health Care.Go here to buy tickets and go here to sign up for Reason's NYC Events newsletter.
